What are the side effects and adverse effects of linezolid?

Linezolid Side Effects

Linezolid causes significant hematologic toxicity (particularly thrombocytopenia and anemia), peripheral and optic neuropathy, lactic acidosis, and gastrointestinal disturbances, with most serious adverse effects occurring with prolonged use beyond 2-4 weeks. 1, 2

Common Side Effects (Occurring in >2% of Patients)

Gastrointestinal Effects

• Diarrhea (4-11%) is the most common adverse effect across studies 1, 3
• Nausea (3-9.6%) and vomiting (3.7%) occur frequently 1, 3
• Headache affects 2-11.3% of patients 3
• Oral and vaginal candidiasis (approximately 1%) 1

Hepatic Effects

• Transient increases in liver function tests are common 1

Serious Adverse Effects

Hematologic Toxicity (Most Significant Concern)

Thrombocytopenia is the primary hematologic concern, typically developing within the first 2 weeks of therapy, while anemia manifests more commonly during prolonged treatment courses. 4, 5

• Myelosuppression affects multiple cell lines and is generally reversible upon discontinuation 6, 3
• Thrombocytopenia occurs more frequently than anemia and neutropenia 6, 2
• Weekly complete blood counts are mandatory for patients receiving linezolid, particularly those treated >2 weeks 3
• More frequent monitoring is required for patients with pre-existing myelosuppression, renal insufficiency, or concurrent bone marrow-suppressing drugs 3

Key Risk Factors for Thrombocytopenia: 4, 5

• Linezolid trough concentrations >8 mg/L (strongly associated with toxicity) 2
• Renal impairment
• Low baseline platelet count
• Advanced age
• Low body weight
• Severe liver dysfunction
• Treatment duration >2 weeks

Neurotoxicity (Potentially Irreversible)

Peripheral and optic neuropathy typically occur after 12-20 weeks of treatment and are often irreversible or only partially reversible. 6, 2

Peripheral Neuropathy

• Develops later in treatment course (usually after 12-20 weeks) 2
• May not be reversible even after drug discontinuation 6
• Higher risk in patients with multidrug-resistant tuberculosis and bone infections 4

Optic Neuropathy

• Increased risk with prolonged treatment 1
• Monthly visual acuity and color discrimination testing (Snellen and Ishihara charts) should be performed 1
• Patients must report any vision changes immediately 1, 2
• Many patients can be rechallenged successfully after vision normalizes, some requiring dose reduction to 300 mg daily 2

Metabolic Complications

Lactic Acidosis

• Can occur at any stage during treatment 1, 4
• Results from inhibition of mitochondrial protein synthesis 2
• Requires immediate clinical attention 1

Hyponatremia

• Can develop at any point during therapy 4

Dermatologic Reactions

• Urticaria and rash (2%) 1, 3
• Rare but serious: Stevens-Johnson syndrome and toxic epidermal necrolysis 1

Serotonin Syndrome

Linezolid is a weak, nonselective, reversible monoamine oxidase inhibitor and can cause serotonin syndrome when combined with serotonergic agents. 6, 2

• Avoid concurrent use with selective serotonin reuptake inhibitors 6, 2
• Contraindicated with MAO inhibitors (phenelzine, isocarboxazid, selegiline, moclobemide) or within 2 weeks of discontinuation 1
• Can lead to serious CNS reactions including neuroleptic malignant syndrome-like reactions 2

Cardiovascular Effects

• Enhanced pressor response with pseudoephedrine or phenylpropanolamine 3
• Patients should avoid large amounts of tyramine-rich foods 1, 3

Dose-Related Toxicity Patterns

An adverse event rate of 58.9% (hematological, neurological, and gastrointestinal) was reported in patients treated with dosages >600 mg/day, compared to 46.7% with 600 mg/day. 2

• Hematological toxicity can occur quickly after starting treatment 2
• Neurotoxicity occurs later, usually after 12-20 weeks 2
• Toxicity associated with trough levels >2.0 mg/L 2

Special Population Considerations

Pediatric Patients

• Linezolid causes less bone marrow suppression in children than in adults 6
• Most common adverse events: diarrhea, vomiting, loose stools, and nausea 6
• Myelosuppression is common at the currently recommended dose of 10 mg/kg twice daily in children <10 years 2
• Oral suspension may not be tolerated due to taste 6

Patients with Renal Impairment

• No dose adjustment required, but use with caution 1
• Two primary metabolites may accumulate in severe renal impairment 1
• Monitor for adverse effects closely 1

Patients with Liver Disease

• No dose adjustment required, but use with caution due to limited clinical data 1
• Monitor for adverse effects closely 1

Monitoring Requirements

Strict clinical monitoring is necessary for patients on long-term linezolid therapy: 2

• Weekly CBC for first 2 months, then monthly if stable 1
• Monthly visual acuity and color discrimination testing 1
• Monitor for peripheral neuropathy symptoms 2
• Weekly CPK levels not required (unlike daptomycin) but monitor for muscle symptoms
• Consider therapeutic drug monitoring to maintain trough levels <8 mg/L and reduce adverse events 2

Contraindications

Absolute contraindications include: 1

• Hypersensitivity to linezolid
• Concurrent use with MAO inhibitors or within 2 weeks of discontinuation
• Uncontrolled hypertension
• Pheochromocytoma
• Carcinoid tumor
• Thyrotoxicosis
• Bipolar depression, schizophrenia, or acute confusional states
• Breastfeeding

Clinical Pitfalls

• Most adverse effects develop after prolonged administration (>2 weeks) and typically subside after discontinuation 7
• Peripheral or optic neuropathy requires even longer duration (3-6 months) to develop 7
• Consider dose reduction to 300 mg daily if serious adverse effects develop, particularly for visual toxicity recurrence 1, 2
• Pregnancy category C - use with caution 6